Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease
- 1 January 1994
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 39 (1), 9-14
- https://doi.org/10.1007/bf02090053
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Pharmacological Aspects and Therapeutic Effects of Ursodeoxycholic AcidDigestive Diseases, 1990
- Is measurement of type III procollagen amino propeptide useful in primary biliary cirrhosis?Journal of Hepatology, 1989
- TYPE III PROCOLLAGEN PEPTIDE: A MARKER OF DISEASE ACTIVITY AND PROGNOSIS IN PRIMARY BILIARY CIRRHOSISThe Lancet, 1988
- DETERIORATION OF PRIMARY BILIARY CIRRHOSIS DURING TREATMENT WITH URSODEOXYCHOLIC ACIDThe Lancet, 1988
- Serum hyaluronate in primary biliary cirrhosis—A biochemical marker for progressive liver damageHepatology, 1988
- IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?The Lancet, 1987
- Persistent elevation of the aminoterminal peptide of procollagen type III in serum of patients with acute viral hepatitis distinguishes chronic active hepatitis from resolving or chronic persistent hepatitisJournal of Hepatology, 1986
- The N-terminal propeptide of collagen type III in serum as a prognostic indicator in primary biliary cirrhosisJournal of Hepatology, 1986
- Increased serum levels of hyaluronate in liver diseaseHepatology, 1985
- The N-Terminal Propeptide of Collagen Type III in Serum Reflects Activity and Degree of Fibrosis in Patients with Chronic Liver DiseaseHepatology, 1984